DE60312474D1 - 5-ht3-rezeptorantagonisten und verwendungsverfahren - Google Patents

5-ht3-rezeptorantagonisten und verwendungsverfahren

Info

Publication number
DE60312474D1
DE60312474D1 DE60312474T DE60312474T DE60312474D1 DE 60312474 D1 DE60312474 D1 DE 60312474D1 DE 60312474 T DE60312474 T DE 60312474T DE 60312474 T DE60312474 T DE 60312474T DE 60312474 D1 DE60312474 D1 DE 60312474D1
Authority
DE
Germany
Prior art keywords
receptor antagonists
use method
provides methods
subject invention
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60312474T
Other languages
English (en)
Other versions
DE60312474T2 (de
Inventor
Xiaming Zhang
Jurg R Pfister
Cyrus Becker
Pascal Druzgala
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aryx Therapeutics Fremont Calif Us
Original Assignee
ARYx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ARYx Therapeutics Inc filed Critical ARYx Therapeutics Inc
Publication of DE60312474D1 publication Critical patent/DE60312474D1/de
Application granted granted Critical
Publication of DE60312474T2 publication Critical patent/DE60312474T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60312474T 2002-01-18 2003-01-21 5-ht3-rezeptorantagonisten und verwendungsverfahren Expired - Lifetime DE60312474T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35050402P 2002-01-18 2002-01-18
US350504P 2002-01-18
PCT/US2003/001876 WO2003061657A1 (en) 2002-01-18 2003-01-21 5-ht3 receptor antagonists and methods of use

Publications (2)

Publication Number Publication Date
DE60312474D1 true DE60312474D1 (de) 2007-04-26
DE60312474T2 DE60312474T2 (de) 2007-12-06

Family

ID=27613396

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60312474T Expired - Lifetime DE60312474T2 (de) 2002-01-18 2003-01-21 5-ht3-rezeptorantagonisten und verwendungsverfahren

Country Status (9)

Country Link
US (3) US6770655B2 (de)
EP (1) EP1465629B1 (de)
JP (1) JP2005523892A (de)
AT (1) ATE356623T1 (de)
AU (1) AU2003210610B2 (de)
CA (1) CA2473392A1 (de)
DE (1) DE60312474T2 (de)
ES (1) ES2281646T3 (de)
WO (1) WO2003061657A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7049326B2 (en) * 2000-05-12 2006-05-23 The University Of Toledo Method and compositions for temporarily incapacitating subjects
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
GB0216027D0 (en) 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
CA2473392A1 (en) * 2002-01-18 2003-07-31 Aryx Therapeutics 5-ht3 receptor antagonists and methods of use
JP2006516977A (ja) 2003-01-13 2006-07-13 ダイノゲン ファーマシューティカルズ，インコーポレイテッド 悪心、嘔吐、レッチング、またはそれらの任意の組み合わせの治療方法
NZ541008A (en) * 2003-01-13 2007-09-28 Dynogen Pharmaceuticals Inc Method of treating functional bowel disorders
DE602004007225T2 (de) * 2003-04-04 2008-03-06 Dynogen Pharmaceuticals Inc., Waltham Methode zur behandlung von erkrankungen der unteren harnwege
CA2573209A1 (en) * 2004-07-14 2006-01-19 Novartis Ag Combination of dpp-iv inhibitors and compounds modulating 5-ht3 and/or 5-ht4 receptors
WO2006105117A2 (en) * 2005-03-28 2006-10-05 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
HK1150388A1 (en) * 2008-01-25 2011-12-23 Medivation Technologies Inc New 2,3,4,5-tetrahydro-1h-pyrido[4,3-b]indole compounds and methods of use thereof 2345--1h-[43-b]
RU2544856C2 (ru) * 2008-01-25 2015-03-20 Сергей Олегович Бачурин НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
NZ588715A (en) 2008-05-29 2012-11-30 Albany Molecular Res Inc 5-ht3 receptor modulators, methods of making, and use thereof
ES2432618T3 (es) 2009-05-20 2013-12-04 Inserm (Institut National De La Santé Et De La Recherche Medicale) Antagonistas del receptor 5-HT3 de serotonina para usar en el tratamiento o prevención de una patología del oído interno con déficit vestibular
DK2432467T3 (en) 2009-05-20 2018-04-16 Inst Nat Sante Rech Med SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS FOR USE IN TREATMENT OF VESTIBULAR DAMAGE LESSONS
CA2827642A1 (en) 2011-02-18 2012-11-15 Medivation Technologies, Inc. Compounds and methods of treating diabetes
US10092550B2 (en) 2014-10-21 2018-10-09 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof
US9907786B2 (en) 2014-10-21 2018-03-06 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
US10659046B2 (en) * 2015-09-25 2020-05-19 Intel Corporation Local cell-level power gating switch

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202343A (en) * 1986-11-28 1993-04-13 Glaxo Group Limited Tricyclic ketones useful as HT3 -receptor antagonists
GR871809B (en) * 1986-11-28 1988-03-07 Glaxo Group Ltd Process for the preparation of tricyclic ketones
DE3851597T2 (de) 1987-09-03 1995-01-26 Glaxo Group Ltd., London Lactamderivate.
HU207078B (en) * 1988-08-02 1993-03-01 Glaxo Group Ltd Process for producing lactam derivatives and pharmaceutical compositions comprising such compounds
ES2088389T3 (es) 1988-08-02 1996-08-16 Glaxo Group Ltd Derivados de lactamas.
GB9106571D0 (en) * 1991-03-27 1991-05-15 Erba Carlo Spa Derivatives of substituted imidazol-2-one and process for their preparation
GB9721139D0 (en) 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments
MXPA02003122A (es) 1998-03-31 2004-04-21 Inst For Pharm Discovery Inc Acidos indolalcanoicos substituidos.
CA2473392A1 (en) * 2002-01-18 2003-07-31 Aryx Therapeutics 5-ht3 receptor antagonists and methods of use

Also Published As

Publication number Publication date
US20030158221A1 (en) 2003-08-21
US20040220246A1 (en) 2004-11-04
WO2003061657A1 (en) 2003-07-31
US7501436B2 (en) 2009-03-10
US6770655B2 (en) 2004-08-03
EP1465629A1 (de) 2004-10-13
CA2473392A1 (en) 2003-07-31
ATE356623T1 (de) 2007-04-15
DE60312474T2 (de) 2007-12-06
US20070197580A1 (en) 2007-08-23
US7125886B2 (en) 2006-10-24
JP2005523892A (ja) 2005-08-11
AU2003210610B2 (en) 2007-11-29
ES2281646T3 (es) 2007-10-01
EP1465629B1 (de) 2007-03-14

Similar Documents

Publication Publication Date Title
DE60312474D1 (de) 5-ht3-rezeptorantagonisten und verwendungsverfahren
DE60222396D1 (de) N-(2-arylethyl) benzylamine als 5-ht6 rezeptor-antagoniste
NO983431D0 (no) Anti-kl°emidler
EA200601555A1 (ru) Замещенные индазол-о-глюкозиды
EA200601554A1 (ru) Замещенные индол-о-глюкозиды
NO20050429L (no) Substituert kinolin-CCR5-reseptorantagonister
DK3530673T3 (da) Humaniserede anti-beta7-antagonister og anvendelser deraf
DE60212801D1 (de) Verwendung azetidinone-substituierter verbindungen zur behandlung der sitosterolhämie
EA200601552A1 (ru) Замещенные конденсированные гетероциклические с-гликозиды
SE0202465D0 (sv) New compounds
EA200601553A1 (ru) Замещенные бензимидазол-, бензтриазол- и бензимидазолон-о-глюкозиды
DE602006007556D1 (de) Heteroarylsulfonylstilbene als 5-ht2a-antagonisten
IS8377A (is) Arýlindenópyridín og arýlindenópyrimidín og notkun þeirra sem mótlyf A2A viðtaka adenósíns
NO20055741L (no) Nye kjemiske forbindelser
DE602004016499D1 (de) Zusammensetzungen und verfahren zur behandlung von entzündlicher darmerkrankung
GEP20074192B (en) Agonism of the 5ht2a receptor for treatment of thermoregulatory dysfunction
CY1105980T1 (el) Βελτιωμενη διαδικασια παρασκευης υδροβρωμικου αλατος του αλφα-πολυμορφικου ελετριπτανιου
DE502004011551D1 (de) 1,3,4-substituierte pyrazole als 5-ht rezeptor-antagonisten zur behandlung von psychosen und neurologischen störungen
DE60018707D1 (de) Anti-androgene und verfahren zur behandlung von krankheiten
AU2003274307A1 (en) 5-ht 1b/1d receptor agonists for the treatment of headache resulting from administering an endothelin receptor antagonist
GB0103045D0 (en) Organic Compounds
DE60319989D1 (de) Diazabicylononan - und decanderivate und ihre verwendung als opioid-rezeptorligande
SE0303418D0 (sv) New use 1
SE0303489D0 (sv) New use VII
SE0301794D0 (sv) New use III

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: ARYX THERAPEUTICS, FREMONT, CALIF., US

8364 No opposition during term of opposition